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 3 
Despite its many shortcomings, the Psoriasis Area and Severity Index (PASI) 51 
remains the standard method worldwide for psoriasis assessment1. Several studies 52 
have implemented electronic versions without evidence of formal validation, raising 53 
the possibility of lack of equivalence with the paper counterpart2. This study aimed at 54 
comparing the conventional paper-based and a novel electronic application version 55 
of the PASI (Figure 1). International Society for Pharmacoeconomics and Outcomes 56 
Research (ISPOR) guidelines3 were followed to assess rater preference and 57 
consistency of scores.  58 
 59 
The study employed a randomized cross-over design using a within-subjects 60 
comparison of the two formats of the PASI. The study was conducted at the 61 
dermatology outpatient department, University Hospital of Wales, Cardiff, UK. 62 
Inclusion criteria were: patients aged 18 years or older with a clinical diagnosis of 63 
chronic plaque psoriasis from a dermatologist and the ability to read and understand 64 
English. Raters ranged from medical students to senior trainees and received 65 
standardised clinical training for PASI assessment to ensure uniformity of rating. The 66 
study power was 80%, with an expected intra-class correlation coefficient (ICC) of 67 
0.9 (α = 0.05), resulting in a target sample size of 44 patients. 68 
 69 
All three raters showed high correlation in test scores (Pearson-correlation 0.949, 70 
p<0.05, n=5) demonstrating standardisation of the assessment criteria. Forty-four 71 
patients were recruited, mean age 45 years (SD ± 16, 59.1% male). The mean 72 
duration of chronic plaque psoriasis diagnosis was 19.2 years (SD ± 14.8, 73 
interquartile range, IQR, 8-30), with PASI severity ranging from 0.7 to 28.5.  The ICC 74 
showed high concordance between the total PASI scores from paper and iPad 75 
 4 
format (ICC = 0.993; 95% CI 0.988-0.996, Table 1). The median difference in PASI 76 
scores was also within the hypothesized difference of CC = 0.993 (p=0.72). The 77 
lower and higher limits of agreement were -1.4 and 1.4, respectively.  78 
The PASI iPad® version demonstrated reduced inter-rater variability compared to 79 
the paper version (Pearson correlation 0.982 vs 0.949, number of patients 80 
assessed=5). There was no carryover effect demonstrated with scores (p=0.82) or 81 
time to completion (p=0.16) regardless of which format of the PASI was used first.  82 
The raters, using a stopwatch, took a median of 147 seconds (iPad®) versus 152 83 
seconds (paper), not including calculation time (p=0.81). Raters reported that the 84 
iPad version was easier to use compared to the paper version due to the visual 85 
nature of the application allowing accurate assessment and calculation of severity 86 
scores, though suggestions were made to improve the user interface.  87 
 88 
The future of medical practice is intricately anchored within the evolution of digital 89 
technology. There is high correlation, and thus equivalence, between the PASI 90 
iPad® and paper versions. The raters preferred the iPad version due to the visual 91 
nature of the scoring process and the reduced likelihood of calculation errors. The 92 
higher inter-rater reliability and the inherent advantages of electronic tools4 further 93 
re-enforces the superiority of the digital format. The validated Psoriasis 360 94 
application©, together with the previously validated DLQI5 component, has the 95 
potential to be of considerable value to clinicians, researchers and patients. 96 
 97 
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TABLES 123 
 124 
 125 
Table 1 Equivalence analysis of paper and electronic PASI overall mean scores and 126 
mean completion time 127 
 
 
    
 Paper iPad® ICC* 
(95% CI) 
Difference 
(P – I) 
Limits of 
agreement‡ 
PASI scores 
(n=104) 
 lower upper 
Median (IQR)  5.7 (2.1-
10.7) 
5.8 (2.7-
9.3) 
0.993  
(0.988 – 
0.996) 
0.0 (-0.3 – 
0.4)† 
-1.4 1.4 
PASI times 
(mins:seconds) 
 
Median (IQR) 2:32 
(01:55-
03:07) 
2:27 
(01:54- 
03:00) 
0.444  
(0.148 – 
0.665) 
-00:10 (-
00:31-
00:40)† 
  
 128 
CI = confidence interval, ICC = intraclass correlation, IQR = interquartile range, SD = 129 
standard deviation  130 
P-I = Paper - iPad® 131 
* Hypothesizing coefficient of ≥ 0.9 132 
† p value > 0.05 calculated by Wilcoxon Signed Rank test 133 
‡ Limits of agreement calculated from Bland-Altman plots 134 
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Figures 147 
 148 
Figure 1 Example screenshot from the PASI iPad App  149 
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